Clinical trials are becoming more complex and the efforts to optimise drug development are rapidly evolving. This Q&A gives a short overview of the strategies Bristol Myers Squibb implements to incorporate diversity into the clinical trial development process with the intent to enhance equity and inclusion for the diverse patient community that uses the treatments we develop. Medical Writing. 2023;32(3):74–75. https://doi.org/10.56012/ugmu9329